Prelude Therapeutics Incorporated — Company profile
Healthcare · Biotechnology · United States
Last price 4.1 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 422.28M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Details
| Name | Prelude Therapeutics Incorporated |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 79 |
| Founded | 2016 |
| Ipo Date | 2020-09-25 |
| Ceo | Krishna Vaddi |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 19.00 |
| Isin | US74065P1012 |
| Cusip | 74065P101 |
| Cik | 1678660 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Krishna Vaddi D.V.M., Ph.D. | Founder, Chief Executive Officer and Director |
| Bryant David Lim J.D. | Chief Financial Officer, Chief Legal Officer and Corporate Secretary |
| Dr. Peggy A. Scherle Ph.D. | Chief Scientific Officer |
| Aimee Crombie Ph.D. | Senior Vice President and Head of Strategic Planning and Operations |
| Dr. Madhu Pudipeddi Ph.D. | Senior Vice President of Technical Operations |
| Robert A. Doody Jr. | Senior Vice President of Investor Relations |
| Michele Porreca M.B.A. | Chief People Officer |
| Dr. Andrew P. Combs Ph.D. | Executive Vice President and Chief Chemistry Officer |
| Naveen Babbar Ph.D. | Senior Vice President of Translation Medicine |
| Dr. Wan-Jen Hong M.D. | Senior Vice President of Clinical Development |
Contact
| Address | 175 Innovation Boulevard, Wilmington, Delaware 19805, United States |
| Phone | 302 467 1280 |
| Website | https://preludetx.com |